Foghorn Therapeutics Inc

+0.84 (+5.53%)
Strategic Combinations, Earnings Announcements

Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets

Published: 12/13/2021 11:30 GMT
Foghorn Therapeutics Inc (FHTX) - Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform.
Foghorn Therapeutics Inc. - Collaboration Includes Three Additional Discovery Programs.
Foghorn Therapeutics - to Receive $300 Million Upfront and an Equity Investment by Lilly of $80 Million at $20 per Share.
Foghorn Therapeutics - for Brm-selective Program and Additional Undisclosed Target Program, Foghorn Will Lead Discovery and Early Research Activities.
Foghorn Therapeutics Inc. - May Receive Up to a Total of $1.3 Billion in Potential Development and Commercialization Milestones.
Foghorn Therapeutics Inc. - Foghorn and Lilly Will Share 50/50 in U.S. Economics.
Foghorn Therapeutics - Eligible to Receive Royalties on Ex-u.s. Sales Starting in Low Double-digit Range & Escalating Into Twenties Based on Revenue Levels.
Foghorn Therapeutics Inc. - There Will Be No Change to Lilly's 2021 Non-GAAP Earnings per Share Guidance As a Result of Transaction.
Revenue is expected to be $0.16 Million
Adjusted EPS is expected to be -$0.45

Next Quarter Revenue Guidance is expected to be $4.77 Million
Next Quarter EPS Guidance is expected to be -$0.54

More details on our Analysts Page.